switching from a biologic to a biosimilar drug in canada
Published 1 year ago • 328 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
1:30
switching from a biologic to biosimilar drug for ibd in ontario
-
5:17
ibd: switching from a biologic to a biosimilar
-
1:08
the impact of switching from a reference biologic to a biosimilar
-
2:52
what's health canada saying about biosimilars?
-
0:47
biosimilars video series: the decision to transition from an original biologic to a biosimilar
-
6:07
manufacturing of biologics
-
15:10
cracking the biosimilar code with biocon's kiran mazumdar shaw
-
7:28
safety concerns rise over the use of biologic drugs
-
1:18
the rise of biosimilars in canadian healthcare
-
10:00
ibd clinical case: the process of switching from a reference biologic to a biosimilar
-
7:21
biologic drugs and biosimilars
-
44:11
biosimilars for ibd: making the transition webinar
-
1:58
transitioning to a biosimilar the patient journey
-
4:41
biologics, unbranded biologics, and biosimilars - what is the difference?
-
1:21
a guide to transitioning to biologic therapy for ibd
-
57:41
webinar: biologics & biosimilars
-
4:09
better understanding biosimilar medications
-
3:33
biosimilars: manufacturing and inherent variation
-
53:30
switching to biosimilars: a conversation with peter taylor
-
56:39
cadth webinar — biologics and biosimilars
-
5:20
data requirements for biosimilars
-
4:21
biosimilars - making the switch